Hit Identification through to
Development Candidate


LATEST NEWS FROMSYGNATURE

Keapstone Therapeutics and Sygnature Discovery collaborate to discover new therapies for Parkinson’s and Motor Neuron Disease

Build your career with
Sygnature Discovery

Your expert partner in
Drug Discovery


LATEST NEWS FROMSYGNATURE

Sygnature has made the annual Sunday Times Lloyds SME Export Track 100 listing for the 3rd consecutive year due to the company’s increasing international client base.

  • Medicinal Chemistry

  • Bioscience

  • Computational Chemistry

  • DMPK and Physical Sciences

Copyright © 2017 Sygnature Discovery

Website built by AtomicMedia - Design by Freestyle.